Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04746677
Other study ID # G200288
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 15, 2021
Est. completion date December 31, 2030

Study information

Verified date March 2024
Source Beth Israel Deaconess Medical Center
Contact Theresa Bishop, BSN
Phone 617-632-9975
Email tbishop@bidmc.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to examine the safety and effectiveness of physician-modified endovascular grafts (PMEGs) for endovascular repair of complex aortic pathology in high-risk patients. The study is divided into three study arms based on the subject's aortic pathology: (1) Complex abdominal aortic aneurysm (AAA); (2) Thoracoabdominal aortic aneurysm; and (3) Aortic dissection.


Description:

Complex aortic pathology, comprised of aneurysmal disease and aortic dissection involving the visceral aortic segment, presents a technical challenge for repair due to involvement of the renal and/or mesenteric arteries. Traditionally, the gold standard for repair has been open repair. However, open repair of these diseases is associated with high perioperative morbidity and mortality. Therefore, for patients with significant medical comorbidities or complex surgical/anatomical features, the risk of open surgery may be prohibitive. As endovascular techniques have become increasingly advanced, options for the endovascular treatment of complex aortic pathology involving the visceral segment have been developed. The predominant approach is fenestrated or branched endovascular aortic repair (F/B-EVAR) with fenestrated or branched endovascular grafts. Currently, there is only one device FDA-approved for commercial use in the United States, the Zenith Fenestrated AAA Endovascular Graft (Cook Medical, Bloomington, IN). However, its use is limited by the design specifications of the device and the required manufacturing time in patients requiring more urgent repair. Therefore, many patients with complex aortic pathology are not eligible for repair with this device, and there are currently no other FDA-approved options for definitive repair. One option for definitive repair of complex aortic pathology in patients ineligible for the Zenith fenestrated device is endovascular repair with a physician-modified endovascular graft (PMEG). For this procedure, the operating surgeon modifies an FDA-approved endovascular graft to incorporate fenestrations or branches based on the patient's anatomy. Numerous reports have been published demonstrating that this procedure can be performed with high technical success, and acceptable perioperative and mid-term results in high-risk patients. The primary objective of the study is to evaluate safety and effectiveness of PMEGs for the endovascular repair of complex aortic pathology in high-risk patients. The safety outcomes include perioperative mortality (defined as death <30 days postoperative or during the index hospitalization) and major adverse events, along with mortality and adverse events during follow-up. Effectiveness outcomes include initial technical success, endoleak rate, target vessel patency, and rate of reintervention. Patients will be followed for five years. Patients will be evaluated preoperatively, at the time of the procedure, at the time of discharge from the index hospitalization, 1-month post-procedure, 6-months post-procedure, and 1-year post-procedure, and annually for five-years.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date December 31, 2030
Est. primary completion date December 31, 2029
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility INCLUSION CRITERIA: General inclusion criteria (applicable to all 3 study arms): - Aortic pathology that fits one of the study arms (see below for detailed description) - Aortic pathology that cannot be treated within the Instructions for Use of an FDA- approved, commercially-available device - Aortic aneurysm that can be treated within the Instructions for Use of an FDA-approved, commercially-available custom-manufactured device but deemed unsafe to wait the required time for device manufacturing - Subject is at high-risk of morbidity and mortality with open surgical repair based on cardiopulmonary function, extent of comorbid disease, and anatomic complexity - Iliac and/or femoral access vessel morphology that is compatible with vascular access techniques, devices, or accessories, with or without use of a surgical or endovascular conduit - Non-aneurysmal aortic segment proximal to the aortic pathology with a: - Minimum neck length of 20 mm - Diameter between 20 - 42 mm - Non-aneurysmal aortic or iliac segment distal to the aortic pathology with: - Aortic distal fixation site greater than 20 mm in length and diameter between 20-42 mm - Iliac artery distal fixation site greater than 10 mm in length and diameter range 8- 25 mm - Age =21 years old - Life expectancy: =2 years Arm1: - Complex abdominal aortic aneurysm, specifically juxtarenal or suprarenal abdominal aortic aneurysm or type IV thoracoabdominal aortic aneurysm, with maximum diameter of =5.5 cm for men or =5.0 cm for women, growth =0.5 cm in 6 months, or concomitant iliac aneurysm =3 cm - Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease extending above the diaphragmatic hiatus - Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease above the diaphragmatic hiatus - Saccular complex abdominal aortic aneurysm deemed at significant risk for rupture - Symptomatic complex aortic aneurysm - Penetrating aortic ulcer with depth =1 cm or width =2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus - Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus Arm2: - Type I, II, or III thoracoabdominal aortic aneurysm with maximum diameter of =5.5 cm, or growth =0.5 cm in 6 months - Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair with aneurysmal disease extending above the diaphragmatic hiatus - Prior thoracic endovascular aneurysm repair with loss of distal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair - Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, with aneurysmal disease above the diaphragmatic hiatus - Saccular type I, II, or III thoracoabdominal aortic aneurysm deemed at significant risk for rupture - Symptomatic type I, II, or III thoracoabdominal aortic aneurysm - Penetrating aortic ulcer with depth =1 cm or width =2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus - Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus Arm 3: - Acute or chronic type B aortic dissection with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or persistence of symptoms despite optimal medical therapy - Prior repair of type A dissection and development of acute or chronic type B dissection component with indication for repair (listed above) - Aortic intramural hematoma (IMH) with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or more typically, persistence of symptoms despite optimal medical therapy Arm 4 - Patient does not meet the inclusion/exclusion criteria of Arms 1 - 3 - Patient has prohibitive operative risk for open repair and no other viable endovascular treatment option - Estimated perioperative risk is lower than the estimated 1-year mortality without surgery EXCLUSION CRITERIA: General Exclusion Criteria - Subject is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site - Subject is unwilling to comply with the follow-up schedule - Inability or refusal to give informed consent by subject or legal representative - Subject is pregnant or breastfeeding - Subject has a ruptured aneurysm Medical Exclusion Criteria - Known sensitivities or allergies to the materials of construction of the devices - Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed - Uncorrectable coagulopathy - Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment - Systemic or local infection that may increase the risk of endovascular graft infection - Diagnosis of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome) Anatomic Exclusion Criteria - Inability to perform open or endovascular iliac conduit in patients with inadequate femoral/iliac access - Excessive thrombus or calcification within the neck of the aneurysm - Visceral vessel anatomy not compatible with placement of a physician-modified endovascular graft due to occlusive disease or small size

Study Design


Intervention

Device:
Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Endovascular aortic repair with a physician-modified endovascular graft (PMEG)

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Perioperative mortality Rate of death Up to 30-days after surgery
Primary Perioperative major adverse events Rates of:
Stroke
Respiratory failure (defined as postoperative intubation >48 hours or reintubation)
Myocardial infarction
Bowel ischemia requiring treatment
Renal failure requiring dialysis
Acute limb ischemia
Paraplegia
Up to 30-days after surgery
Primary All-cause mortality Rate of death due to any cause at: 30-days, 6-months, 1-year, and annually to 5-years 30-days to 5-years
Primary Aneurysm-related mortality Rate of aneurysm-related death at: 30-days, 6-months, 1-year, and annually to 5-years 30-days to 5-years
Primary Long-term major adverse events Rate of major adverse events at: 6-months, 1-year, and annually to 5-years
Long-term major adverse event is defined as having at least one of the following:
Death
Stroke (deemed related to the device, the procedure, or a reintervention)
Bowel ischemia requiring treatment (deemed related to the device, the procedure, or a reintervention)
Renal failure requiring dialysis (deemed related to the device, the procedure, reintervention, or follow-up imaging)
Acute limb ischemia (deemed related to the device, the procedure, or a reintervention)
6-months to 5-years
Primary Technical success Defined as successful delivery of the physician-modified graft in the planned location with patency of all intended target vessels and without unintentional coverage of any aortic branches, along with successful removal of the delivery system 24 hours
Primary Device-related reintervention Rate of device-related reintervention at: 30-days, 6-months, 1-year, and annually to 5-years 30-days to 5-years
Primary Aneurysm rupture Rate of aneurysm rupture at: 30-days, 6-months, 1-year, and annually to 5-years 30-days to 5-years
Primary Conversion to open repair Rate of conversion to open repair at: 30-days, 6-months, 1-year, and annually to 5-years 30-days to 5-years
Primary Endoleaks Rate of Type I, II, III, IV, and V endoleaks at: 30-days, 6-months, 1-year, and annually to 5-years 30-days to 5-years
Primary Main device occlusion Rate of main device occlusion at: 30-days, 6-months, 1-year, and annually to 5-years 30-days to 5-years
Primary Target vessel patency Rate of target vessel patency at: 30-days, 6-months, 1-year, and annually to 5-years 30-days to 5-years
Primary Residual aneurysm sac status Rate of residual sac status (stable, regressing, expanding) at 6-months, 1-year, and annually to 5-years, defined as the following:
Stable: maximum diameter within 5 mm of the diameter at 30-day follow-up
Regressing: maximum diameter =5 mm less than the diameter at 30-day follow-up
Expanding: maximum diameter =5 mm greater than the diameter at 30-day follow-up
6-months, 1-year, and annually to 5-years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04227054 - Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks N/A
Active, not recruiting NCT03687489 - Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System N/A
Active, not recruiting NCT03507413 - Metformin Therapy in Non-diabetic AAA Patients Phase 2/Phase 3
Not yet recruiting NCT05756283 - The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair N/A
Not yet recruiting NCT04089241 - Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair N/A
Active, not recruiting NCT02604303 - A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT02224794 - LIFE Study: Least Invasive Fast-Track EVAR
Terminated NCT01843335 - Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair N/A
Completed NCT02229006 - Sodium Fluoride Imaging of Abdominal Aortic Aneurysms N/A
Completed NCT01118520 - AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) Phase 2
Terminated NCT01425242 - Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension N/A
Completed NCT00746122 - Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair N/A
Completed NCT03952780 - Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
Completed NCT00583414 - Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients N/A
Recruiting NCT05864560 - Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
Completed NCT01683084 - Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms Phase 4
Active, not recruiting NCT03180996 - Global Fenestrated Anaconda Clinical sTudy
Completed NCT02493296 - The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
Completed NCT03320408 - Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers